Allos Therapeutics Inc - Current report filing (8-K)
27 Fevereiro 2008 - 9:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
February 27,
2008
ALLOS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and
Financial Condition.
On February 27, 2008, Allos Therapeutics, Inc.,
a Delaware corporation (the Company), issued a press release relating to the
Companys financial results for fiscal year 2007. The press release is
attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of
this report and shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange
Act, regardless of any general incorporation language in such filing.
Section 9 - Financial Statements
and Exhibits
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
99.1 Press Release, dated February 27,
2008, entitled Allos Therapeutics
Reports 2007 Results.
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2008
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
Marc H. Graboyes
|
Its:
|
Vice President, General
Counsel
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press Release, dated
February 27, 2008, entitled Allos
Therapeutics Reports 2007 Results.
|
|
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics Inc